BioLife Solutions (BLFS) to Release Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect BioLife Solutions to post earnings of ($0.25) per share for the quarter. BioLife Solutions has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The business had revenue of $32.73 million during the quarter, compared to analysts’ expectations of $32.70 million. On average, analysts expect BioLife Solutions to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioLife Solutions Trading Down 0.3 %

BLFS opened at $17.48 on Thursday. The company has a fifty day moving average price of $17.35 and a two-hundred day moving average price of $15.57. BioLife Solutions has a 1-year low of $8.92 and a 1-year high of $24.50. The company has a market cap of $791.84 million, a P/E ratio of -11.50 and a beta of 1.67. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group started coverage on BioLife Solutions in a research report on Thursday, April 4th. They issued a “buy” rating and a $22.00 target price for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $23.40.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the transaction, the chief marketing officer now owns 129,644 shares in the company, valued at $2,031,521.48. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Amy Duross sold 6,135 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $16.86, for a total transaction of $103,436.10. Following the transaction, the director now owns 34,508 shares of the company’s stock, valued at $581,804.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total value of $156,700.00. Following the sale, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at approximately $2,031,521.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,996 shares of company stock valued at $562,145. 2.70% of the stock is owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.